ROR1 and breast cancer: Using the annotated I-SPY2 transcriptome data from a cohort of nearly 1000 patients with newly diagnosed high-risk early breast cancer, we found that high-level pretreatment expression of ROR1 or ROR2 had a distinct subtype-specific association with adverse risk.